FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to peptide ligands specific for plasma kallikrein, which can be used in medicine. Peptide ligand is obtained, containing a polypeptide having three cysteine residues separated by two loop sequences, and a molecular scaffold, which is tris(bromomethyl)benzene, which forms covalent bonds with cysteine residues of the polypeptide, so that on the molecular scaffold, two polypeptide loops are formed, which are closed between points of attachment to the scaffold.
EFFECT: invention makes it possible to obtain peptide ligands specific for plasma kallikrein with increased efficiency and / or resistance to proteases.
27 cl, 6 dwg, 10 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | 2015 |
|
RU2708459C2 |
MODULATING THE SPECIFICITY OF STRUCTURED PROTEINS | 2012 |
|
RU2745572C2 |
MODULATION OF SPECIFICITY OF STRUCTURED POLYPEPTIDES | 2014 |
|
RU2674070C2 |
MODULATION OF STRUCTURED PROTEINS SPECIFICITY | 2012 |
|
RU2631931C2 |
ANTIANGIOGENIC COMPOUNDS | 2009 |
|
RU2511420C2 |
AGONISTS OF CORTICOTROPIN-RELEASING FACTOR (CRFR) RECEPTOR AND THEIR USING | 2003 |
|
RU2294333C2 |
AGONISTS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR | 2003 |
|
RU2286995C2 |
CORTICOTROPIN-RELEASING FACTOR RECEPTOR AGONISTS AND USES THEREOF | 2003 |
|
RU2305110C2 |
SELF-ASSEMBLING PEPTIDE NANOPARTICLES EFFECTIVE AS VACCINES | 2009 |
|
RU2540871C2 |
NOVEL MOLECULE INHIBITORS OF JNK | 2011 |
|
RU2570417C2 |
Authors
Dates
2018-12-11—Published
2014-10-28—Filed